Evommune EVMN Gain (loss) on mark-to-market of Escrowed Shares
Gain (loss) on mark-to-market of Escrowed Shares at other companies
Other financials
Where this comes from
Reported directly by Evommune in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnDerivatives.
The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evommune 's gain (loss) on mark-to-market of escrowed shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evommune 's gain (loss) on mark-to-market of escrowed shares?
- Evommune (EVMN) reported gain (loss) on mark-to-market of escrowed shares of $206.46K in Q1 2026.
- How has Evommune 's gain (loss) on mark-to-market of escrowed shares changed year-over-year?
- Evommune 's gain (loss) on mark-to-market of escrowed shares decreased by 88.8% year-over-year, from $1.84M to $206.46K.
- What does gain (loss) on mark-to-market of escrowed shares mean?
- Represents the non-cash impact of changes in the fair value of derivative instruments held by the company. This metric reflects market-driven fluctuations in financial instruments that are marked to market each reporting period. It is critical for understanding how volatility in financial markets or internal equity structures affects the company's reported net income.